Education initiatives aimed at promoting understanding of type 2 diabetes and obesity, combined with successful outcomes from GLP-1 therapies, are leading to higher prescription rates
[56] Senescent cells secrete a harmful mix of inflammatory molecules known as the senescence-associated secretory phenotype (SASP)
Authentic testimonials from staff build the deep trust required to keep patients returning
Liraglutide, like either approved GLP-1 drugs, has been shown to reduce weight, glucose and lipids in patients with Type 2 Diabetes Mellitus but also patients with overweight and obesity
A plateau is common during weight loss because the body changes as weight comes down
As of January 1st, 2022, WADA officially classified BPC-157 as a prohibited substance (9)